专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO2018178029A1 METHODS AND COMPOSITIONS FOR TREATING DEGENERATIVE MUSCULAR AND/OR NEUROLOGICAL CONDITIONS OR DISEASES 审中-公开
公开(公告)号：WO2018178029A1
公开(公告)日：2018-10-04
申请号：PCT/EP2018/057677
申请日：2018-03-26
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) , UNIVERSITE NICE SOPHIA ANTIPOLIS , HOSPICES CIVILS DE LYON , UNIVERSITÉ CLAUDE BERNARD LYON 1 , CENTRE HOPITALIER UNIVERSITAIRE DE NICE , RUIJIN HOSPITAL, SHANGHAI JIAOTONG UNIVERSITY SCHOOL OF MEDICINE
发明人： GILSON, Eric , ROBIN, Jérome , SACCONI, Sabrina , SCHAEFFER, Laurent , YE, Jing
IPC分类号： A61K31/05 , A61K31/192 , A61K31/216 , A61K31/336 , A61K31/353 , A61K31/4439 , A61P25/28 , A61P21/00
摘要： The present invention relates to a method for treating degenerative muscular and/or neurological conditions or diseases. The inventors found that SIRT3 is decreased with age in human striated muscles which are post-mitotic cells. More particularly, in contrast to mitotic cells, downregulation of TRF2 in differentiated myotubes does not lead to telomere deprotection but triggers potent oxidative stress, along with increases in reactive oxygen species (ROS), mitochondrial dysfunction, FOXO3a activation, and autophagy. Thus, the invention relates to a method of treating muscle diseases or neurodegenerative diseases in a subject in need thereof, comprising a step of administering said subject with a therapeutically effective amount of an activator of the expression or activity of SIRT3.

72. 发明申请

WO2017202890A1 METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING MYELOMA 审中-公开
标题翻译：预防和治疗骨髓瘤的方法和组合物
公开(公告)号：WO2017202890A1
公开(公告)日：2017-11-30
申请号：PCT/EP2017/062504
申请日：2017-05-24
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS , CENTRE HOPITALIER UNIVERSITAIRE DE NICE
发明人： LUCIANO, Frédéric , HAMOUDA, Mohamed, Amine , ROBERT, Guillaume , AUBERGER, Patrick , CLUZEAU, Thomas
IPC分类号： G01N33/574
CPC分类号： G01N33/574 , G01N2800/50
摘要： The inventors have used the Εμ-bcl-b transgenic mouse model to study the effect of the Blc-B protein on the evolution of monoclonal gammopathy of undetermined significance (MGUS) to myeloma. They have performed the Bcl-B-positive plasma cell quantification by flow cytometry analysis of bone marrow cells from an MGUS and an multiple myeloma (MM) patient. They have showed that a subject having a high concentration of Bcl-B than a predetermined value is at risk of having myeloma. Accordingly, the invention relates to a method for predicting the risk of having myeloma in a subject suffering from MGUS comprising the steps of: i) measuring the concentration of Bcl-B in a biological sample obtained from said subject, ii) comparing the concentration obtained at step (i) to a predetermined value, and iii) concluding that the subject is at risk of having myeloma when the concentration of Bcl-B is higher than the predetermined value.
摘要翻译：本发明人已经使用了Eμ-bcl-b转基因小鼠模型来研究Blc-B蛋白对具有未定意义的单克隆丙种球蛋白病（MGUS）向骨髓瘤的进化的影响。他们通过对来自MGUS和多发性骨髓瘤（MM）患者的骨髓细胞进行流式细胞术分析来进行Bcl-B阳性浆细胞定量。他们已经表明，具有高于预定值的高浓度Bcl-B的受试者处于患有骨髓瘤的风险中。因此，本发明涉及用于预测患有MGUS的受试者中患有骨髓瘤的风险的方法，其包括以下步骤：i）测量从所述受试者获得的生物样品中Bcl-B的浓度，ii）比较获得的浓度在步骤（i）中达到预定值，以及iii）当Bcl-B的浓度高于预定值时，推断受试者有患骨髓瘤的风险。

73. 发明申请

WO2017129558A1 METHODS FOR PREDICTING OR TREATING MYELOPOIESIS-DRIVEN CARDIOMETABOLIC DISEASES AND SEPSIS 审中-公开
标题翻译：预测或治疗发育不良性心脏病和脓毒症的方法
公开(公告)号：WO2017129558A1
公开(公告)日：2017-08-03
申请号：PCT/EP2017/051418
申请日：2017-01-24
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS
发明人： YVAN-CHARVET, Laurent , VIAUD, Manon , GUINAMARD, Rodolphe
IPC分类号： A61K31/197 , A61K39/00 , A61K45/00 , A61K31/235 , A61K31/166 , A61P9/10 , A61P31/00
CPC分类号： A61K31/235 , A61K31/165 , A61K31/195 , A61K31/197 , A61K31/353 , A61K31/7048 , A61K39/00
摘要： The present invention relates to a method of treating myelopoiesis-driven cardiometabolic diseases and sepsis in a subject in need thereof comprising the step of administering the subject with a therapeutically effective amount of an agent selected from the group consisting of GLUT1 inhibitors and GOTs inhibitors.
摘要翻译：本发明涉及在有需要的受试者中治疗骨髓生成 - 驱动的心脏代谢疾病和脓毒症的方法，包括给予受试者治疗有效量的选自以下的试剂的步骤：的GLUT1抑制剂和GOTs抑制剂。

74. 发明申请

WO2017102841A1 METHODS FOR DIAGNOSING OR PROGNOSING PROSTATE CANCER 审中-公开
标题翻译：诊断或预测前列腺癌的方法
公开(公告)号：WO2017102841A1
公开(公告)日：2017-06-22
申请号：PCT/EP2016/080998
申请日：2016-12-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS
发明人： BENAHMED, Mohamed
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates to methods and kits for diagnosing or prognosing prostate cancer. More particularly, the invention relates to an in vitro method for predicting or diagnosing a prostate cancer in a subject, said method comprising the following steps of: i. measuring the expression levels of miR-101 and miR-195 in a biological sample obtained from said subject; ii. comparing said expression levels of miR-101 and miR-195 with their respective predetermined reference values; and iii. determining whether the subject has or is at risk of having a prostate cancer, wherein an expression level of miR-101 lower than the predetermined reference value and an expression level of miR-195 higher than the predetermined reference value is indicative that the subject has, or is at risk of having a prostate cancer.
摘要翻译：本发明涉及诊断或预后前列腺癌的方法和试剂盒。更具体地，本发明涉及用于预测或诊断受试者中的前列腺癌的体外方法，所述方法包括以下步骤：i。测量从所述受试者获得的生物样品中miR-101和miR-195的表达水平; II。比较miR-101和miR-195的所述表达水平与它们各自的预定参考值; 和iii。确定受试者是否患有前列腺癌或处于患有前列腺癌的风险中，其中低于预定参考值的miR-101的表达水平和高于预定参考值的miR-195的表达水平指示受试者具有，或有患前列腺癌的风险。

75. 发明申请

WO2016150824A1 CAPTEUR A FIBRE OPTIQUE DISTRIBUE D'ETAT DE CONTRAINTE 审中-公开
标题翻译：用于感应应力状态的分布式光纤传感器
公开(公告)号：WO2016150824A1
公开(公告)日：2016-09-29
申请号：PCT/EP2016/055866
申请日：2016-03-17
申请人： THALES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE NICE SOPHIA-ANTIPOLIS
发明人： MOLIN, Stéphanie , DOISY, Martine , PEIGNE, Arnaud , RESIDORI, Stefania , BORTOLOZZO, Umberto , HUIGNARD, Jean-Pierre , BOUFFARON, Renaud , DOLFI, Daniel
IPC分类号： G01D5/353 , G01H9/00
CPC分类号： G01L1/242 , G01D5/353 , G01D5/35306 , G01H9/004
摘要： L'invention concerne un capteur à fibre optique distribué d'état de contrainte dynamique, comprenant : - un ensemble optique configuré pour générer une série d'impulsions optiques (l pi ); - une fibre optique (FO) de longueur optique L; - un système optique configuré pour : o injecter par ladite première extrémité (E x1 ) au moins ladite série d'impulsions optiques (l pi ); o recevoir au niveau de ladite extrémité (E x1 ) au moins une série d'impulsions optiques de sortie, issues desdites impulsions d'entrée après propagation et rétro-propagation dans la fibre; o générer au moins un faisceau de référence continu (Fr) ou des impulsions optiques de référence (l pri ) à partir dudit ensemble optique ou desdites impulsions optique de sortie (I psi ); o réaliser une série de zones d'interférences correspondant à l'interférence entre ledit faisceau de référence (Fr) ou une impulsion de référence (lpri) et une impulsion optique signal (l psiS ) issue d'une impulsion optique de sortie (l psi ); - un détecteur holographique (HD) comprenant : o une valve optique à cristal liquide (LCLV), ladite valve (LCLV) disposée de sorte qu'elle recouvre au moins partiellement lesdites zones d'interférence, et réalisant des hologrammes à partir desdites zones d'interférence; o au moins un détecteur optique (PD) configuré pour détecter des signaux optiques de sortie diffractés par lesdits hologrammes.
摘要翻译：本发明涉及用于感测动态应力状态的分布式光纤传感器，包括： - 被配置为产生一系列光脉冲（lpi）的光学组件; - 光学长度L的光纤（FO）; - 光学系统，被配置为：经由所述第一端（Ex1）注入至少所述一系列光脉冲（lpi）; 在所述端（Ex1）处接收来自光纤中传播和反向传播之后的所述输入脉冲的至少一系列输出光脉冲; o从所述光学组件或所述输出光脉冲（Ipsi）产生至少一个连续参考光束（Fr）或参考光脉冲（lpri）; o产生一系列相应于所述参考光束（Fr）或参考脉冲（lpri）与来自输出光脉冲（lpsi）的信号光脉冲（lpsiS）之间的干扰的干扰区域; - 全息检测器（HD），包括：液晶光阀（LCLV），所述阀（LCLV）以至少部分地覆盖所述干涉区域的方式布置，并且从所述干涉区域产生全息图; o至少一个光学检测器（PD），被配置为检测由所述全息图衍射的输出光信号。

76. 发明申请

WO2016110581A1 CAPTEUR A FIBRE OPTIQUE 审中-公开
标题翻译：光纤传感器
公开(公告)号：WO2016110581A1
公开(公告)日：2016-07-14
申请号：PCT/EP2016/050304
申请日：2016-01-08
申请人： THALES , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE , UNIVERSITE NICE SOPHIA-ANTIPOLIS
发明人： HUIGNARD, Jean-Pierre , BORTOLOZZO, Umberto , DOLFI, Daniel , MOLIN, Stéphanie , PEIGNE, Arnaud , RESIDORI, Stefania
IPC分类号： G01D5/26 , G01H9/00
CPC分类号： G01H9/004 , G01D5/268 , G01D5/35303 , G01D5/35316 , G01D5/35345 , G01D5/35361 , G01D5/35364
摘要： L'invention a pour objet un capteur à fibre optique pour détecter une excitation à proximité d'un ensemble fibre optique, ladite excitation induisant une modulation de la phase d'un signal optique se propageant dans ledit ensemble fibre optique, ledit capteur comprenant: un ensemble laser (SL) émettant au moins un faisceau laser; un ensemble fibre optique (OF); un système optique configuré pour: injecter au moins une partie dudit faisceau laser; générer au moins un faisceau laser signal issu du faisceau laser injecté et propagé dans ledit ensemble fibre; générer au moins un faisceau de référence (Fr) à partir dudit faisceau laser ou dudit faisceau signal; réaliser au moins une zone d'interférence correspondant à l'interférence entre une partie du faisceau de référence et une partie du faisceau signal d'interférence correspondant à l'interférence entre une partie du faisceau de référence et une partie du faisceau signal; un ensemble d'holographie digitale comprenant: un modulateur spatial de lumière à cristal liquide; une caméra configurée pour recevoir ladite zone d'interférence et la transcrire électriquement sur ledit modulateur spatial de lumière à cristal liquide pour y créer un hologramme de phase lui correspondant; au moins un détecteur optique configuré pour détecter un faisceau signal optique de sortie (F out ).
摘要翻译：本发明涉及一种用于检测光纤组件附近的激励的光纤传感器，所述激励引起对通过所述光纤组件传播的光信号的相位的调制，所述传感器包括：激光组件（SL）至少发射一个激光束; 光纤组件（OF）; 光学系统，被配置为：注入所述激光束的至少一部分，产生所述激光束的至少一部分，产生源自注入并通过所述光纤组件传播的激光束的至少一个信号激光束，产生至少一个来自所述激光束或所述信号光束的参考光束（Fr）形成对应于参考光束的一部分与干涉信号光束的一部分之间的干涉的至少一个干涉区域，该部分对应于参考光束的一部分和一部分信号光束; 一种数字全息组件，包括：液晶空间光调制器，配置为接收所述干涉区域并将其电转录到所述液晶空间光调制器上以便在其中产生相应于其中的相位全息图的照相机; 以及配置成检测输出光信号光束（Fout）的至少一个光检测器。

77. 发明申请

WO2014140306A1 METHODS AND COMPOSITIONS FOR PREVENTING METASTASIS AND FOR IMPROVING THE SURVIVAL TIME 审中-公开
标题翻译：用于预防生物化学和改善生存时间的方法和组合物
公开(公告)号：WO2014140306A1
公开(公告)日：2014-09-18
申请号：PCT/EP2014/055154
申请日：2014-03-14
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS
发明人： ROCCHI, Stéphane , BALLOTTI, Robert , CEREZO, Mickael
IPC分类号： C12Q1/68
CPC分类号： A61K31/155 , A61K45/06 , C12Q1/6886 , C12Q2600/106 , C12Q2600/118 , C12Q2600/156 , G01N33/6893 , G01N2800/52 , G01N2800/7028
摘要： The invention relates to an AMPK activator (such as for instance metfomin) for use in preventing metastasis in a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein. The invention also relates to an AMPK activator for use in improving the survival time of a patient suffering from a cancer, wherein said patient has a non-mutated p53 gene or lacks a mutant form of the p53 protein.
摘要翻译：本发明涉及用于预防患有癌症的患者转移的AMPK激活剂（例如metfomin），其中所述患者具有非突变的p53基因或缺乏p53蛋白的突变形式。本发明还涉及用于改善患有癌症的患者的存活时间的AMPK激活剂，其中所述患者具有非突变的p53基因或缺乏p53蛋白的突变体形式。

78. 发明申请

WO2019134946A1 METHODS AND COMPOSITIONS FOR TREATING MELANOMA RESISTANT 审中-公开
公开(公告)号：WO2019134946A1
公开(公告)日：2019-07-11
申请号：PCT/EP2019/050118
申请日：2019-01-03
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS
发明人： BERTOLOTTO, Corine , OHANNA, Mickaël , BALLOTTI, Robert
IPC分类号： G01N33/574 , C12Q1/48
CPC分类号： G01N33/5743 , C12Q1/48 , G01N2333/91142 , G01N2500/04 , G01N2800/54
摘要： The present invention relates to a method for treating a subject suffering from melanoma resistant by administering to said subject an inhibitor of NAMPT. Using a global metabolic profiling, inventors have showed that in addition to glycolysis, the BRAF inhbitor, PLX4032, promoted a complex metabolic rewiring of melanoma cells, including protein catabolism and fatty acid synthesis. Importantly, they observed that PLX4032 reduced the levels of nicotinamide adenine dinucleotide (NAD+), an important redox co-factor in numerous metabolic processes, including glycolysis, tricarboxylic acid cycle (TCA) cycle, glutamate metabolism and fatty acid betaoxidation. Pharmacological or genetic inhibition of NAMPT impaired melanoma cell growth, whereas the overexpression of NAMPT dampened the antiproliferative effect of PLX4032. In vivo, the inhibition of NAMPT also prevented the xenograft development of PLX4032-sensitive and -resistant melanoma cells, identifying NAMPT as a potential target for BRAFi-resistant melanomas.

79. 发明申请

WO2019016310A1 METHODS AND COMPOSITIONS FOR TREATING CANCERS 审中-公开
公开(公告)号：WO2019016310A1
公开(公告)日：2019-01-24
申请号：PCT/EP2018/069619
申请日：2018-07-19
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： GAGGIOLI, Cédric , BERTERO, Thomas
IPC分类号： A61P35/00 , A61K45/06 , A61K31/198 , A61K31/501
CPC分类号： A61K31/501 , A61K31/198 , A61K45/06 , A61K2300/00
摘要： To investigate whether pharmacological inhibition of both glutamino lysis and aspartate/glutamate exchange are relevant therapies for cancer, inventors performed combination treatments in the highly metastatic orthotopic syngenic 4T1 breast cancer mouse model. Namely, whereas either CB839 or TFB-TBOA treatment alone decreases intratumoral aspartate and glutamate concentration, combined treatment led to a greater inhibition. Such metabolic effects further decreased stromal activation as reflected by a-SMA and decreased tumor cell proliferation, as reflected by in situ staining of the proliferation marker PCNA. Consistent with these observations and their in vitro results, CB839 or TFB-TBOA, treatments inhibited 4T1 tumor progression as quantified by tumor volume and lung and liver metastasis. Combined treatment led to greater inhibition of tumor growth and invasion and further improved survival outcomes. Accordingly, the present invention relates to a method for treating cancer in a subject in need thereof comprising a step of administering the subject with a therapeutically effective amount of GLS1 and SLC1A3 inhibitors.

80. 发明申请

WO2018224615A1 METHODS AND COMPOSITIONS FOR TREATING HYPERPIGMENTATION DISORDERS 审中-公开
公开(公告)号：WO2018224615A1
公开(公告)日：2018-12-13
申请号：PCT/EP2018/065082
申请日：2018-06-07
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITE NICE SOPHIA ANTIPOLIS , CENTRE HOPITALIER UNIVERSITAIRE DE NICE
发明人： PASSERON, Thierry , SORMANI LE BOURHIS, Laura
IPC分类号： A61P17/00 , A61K31/713 , C12N15/113
摘要： The present invention relates to a method for treating hyperpigmentary skin disorder. By using normal human melanocytes (NHMs) and normal human keratinocytes (NHKs), which are infected with CLEC12B siRNA/shRNA/RNAi lentiviral particles, inventors have showed that decreasing CLEC12B expression significantly reduce the transfer of melanin to the keratinocytes. These results demonstrate that CLEC12B is specifically expressed in the skin by melanocytes and plays a key role in the transfer or melanosomes to the keratinocytes. Accordingly, the invention relates to a method for treating hyperpigmentary skin disorder in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a CLEC12B antagonist, wherein CLEC12B antagonist is polypeptide, more particularly a decoy.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式